Please login to the form below

Not currently logged in
Email:
Password:

Increlex

This page shows the latest Increlex news and features for those working in and with pharma, biotech and healthcare.

EMA publishes European drug shortage details

EMA publishes European drug shortage details

First public list contains details on Cerezyme, Fabrazyme, Increlex and Vistide. ... The two other drugs with shortages assessed by the EMA are Ipsen's Increlex (mecasermin), for people with a growth disorder due to severe primary insulin-like growth

Latest news

  • North-South divide?

    As such, treatments for high need, orphan conditions have been approved with costs per QALY potentially above £40, 000 (46, 000), like mecasermin (Increlex) for growth failure in children and nelarabine

  • Reaching new heights

    A compelling video illustrated the case of the first UK patient diagnosed with Severe Primary IGFD and treated with Recombinant human insulin-like growth factor-I (rhIGF-I), Increlex. ... 75 per cent were 'considerably more confident' in using rhIGF-1

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...